Other News To Note

• PharmAthene Inc., of Annapolis, Md., said the FDA lifted the partial clinical hold imposed last year on Valortim, a fully human anti-toxin monoclonal antibody being developed for the prevention and treatment of inhalational anthrax, clearing the company to move forward with a Phase I intravenous dose-escalation study in the coming weeks, which Roth Capital Partners analyst Joseph Pantginis called an "encouraging event" for the company.